Related Experiment Video

Updated: Jun 4, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients

R Lacchini1, A L B Jacob-Ferreira, M R Luizon

  • 1Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil.

Journal of Human Hypertension
|February 11, 2011
PubMed

Insights

Genetic variations in matrix metalloproteinase-2 (MMP-2) influence cardiac remodeling in hypertension. Specific MMP-2 gene polymorphisms are linked to reduced left ventricular mass and dimensions in hypertensive patients.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Hypertension Research

Background:

  • Matrix metalloproteinases (MMPs), particularly MMP-2, play a crucial role in cardiac remodeling processes.
  • Hypertension is a major risk factor for adverse cardiac remodeling, leading to increased left ventricular mass and dysfunction.
  • Understanding the genetic underpinnings of cardiac remodeling in hypertension is essential for developing targeted therapies.

Purpose of the Study:

  • To investigate the association between matrix metalloproteinase-2 (MMP-2) gene polymorphisms and hypertension.
  • To determine if MMP-2 genetic variations are linked to left ventricular (LV) remodeling in hypertensive individuals.
  • To explore the impact of MMP-2 genotypes and haplotypes on echocardiographic parameters of LV remodeling.

Main Methods:

  • Study included 160 hypertensive patients and 123 healthy controls.
  • Echocardiography was performed to assess left ventricular mass index (LVMI) and end-diastolic diameter (EDD).
  • MMP-2 gene polymorphisms C(-1306)T (rs243865) and C(-735)T (rs 2285053) were analyzed, along with MMP-2 haplotypes using Haplo.stats.

Main Results:

  • The 'CC' genotype at the C(-1306)T polymorphism was associated with reduced LVMI and LV end-diastolic diameter (P=0.0365 and P=0.0438).
  • The 'C, C' MMP-2 haplotype correlated with decreased LVMI and EDD (P=0.0278 and P=0.0322).
  • The 'T, C' haplotype was more prevalent in the highest quartile of LVMI (P=0.0187) and associated with an increased risk of higher LVMI (OR=3.5121).

Conclusions:

  • MMP-2 gene polymorphisms significantly influence hypertension-induced left ventricular remodeling.
  • Specific MMP-2 genotypes and haplotypes may serve as genetic markers for predicting the extent of cardiac remodeling in hypertensive patients.
  • These findings highlight the role of MMP-2 in the pathophysiology of hypertensive heart disease.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...